Anavex Life Sciences Corp. Stock News

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape

In financial markets, it's often said that cash is king. That's something to remember when it comes to the biotechnology universe due to the cost-intensive nature of developing new drugs and therapies

Aricept and blarcamesine limit further oxidative stress in Alzheimer's disease via agonism of Sigma-1 receptors. Simufilam may do the same.

Anavex Life Sciences Corp (NASDAQ: AVXL ) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson''s Disease Dementia (PDD) study at the AD/PD 2022 International Conference. MDS-UPDRS1 Total score improved significantly by -14.51 for patients treated with … Full story available on Benzinga.com

NEW YORK , March 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, AVXL, AAL, GTLB, and SABR. … Full story available on Benzinga.com

Anavex Life Sciences Corp (NASDAQ: AVXL) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson's Disease Dementia (PDD) study at the AD/PD 2022 Int

On Tuesday, Anavex Life Sciences (AVXL), a clinical-stage biotech focused on treatment for CNS disorders, announced Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001…

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ: CORT), Medallion Financial Corp. (NASDAQ: MFIN), Clariant AG (OTCMKTS: CLZNY), and Anavex Life Sciences Corp. (NASDAQ: AXVL). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated thera

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL ), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer''s disease, Parkinson''s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the Annual Needham Virtual Neuroscience Forum in a fireside chat on Wednesday, March 16 th 2022 at 8:00 AM ET. A live audio webcast will be accessible at https://wsw.com/webcast/needham118/avxl/2274180 or through Company''s website at www.anavex.com . An archived edition of the session will be available later that day. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (NASDAQ: AVXL ) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer''s disease, Parkinson''s disease, Rett syndrome and other central nervous …

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 1, 2022, before the market opened, Anavex announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoint

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated thera

In last trading session, Anavex Life Sciences Corp. (NASDAQ:AVXL) saw 1.78 million shares changing hands with its beta currently measuring 0.70. Company’s recent per share price level of $9.74 trading at -$1.0 or -9.31% at ring of the bell on the day assigns it a market valuation of $758.26M. That closing price of AVXL’s stock … Analysts Say That Anavex Life Sciences Corp. (NASDAQ:AVXL) Is Likely To Make It To $42.00 In 12 Months Read More »

An investigation for investors in Anavex Life Sciences Corp. (NASDAQ:AVXL) shares over potential securities laws violations by Anavex Life Sciences Corp. was announced. San Diego, CA -- ( SBWIRE ) -- 02/23/2022 -- Anavex Life Sciences Corp. is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL), have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Anavex Life Sciences Corp. regarding its business, its prospects and its operations were materially false and misleading at the time they were made. New York based Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Before the market opened on February 1, 2022, Anavex Life Sciences Corp. announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints.

AVXL earnings call for the period ending December 31, 2021.